Wedbush Reiterates Outperform Rating on Telix Pharmaceuticals Ltd (TLX)

November 4, 2026 6:49 AM

Wedbush analyst David Nierengarten reiterated an Outperform rating and $22.00 price target on Telix Pharmaceuticals Ltd (NASDAQ: TLX).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found